ResearcherShanghai Jiao Tong UniversityNo recent work listed
Fu-Rao Liu
Matched on OpenAlex author ID A5059741335. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2017: 2 papers · 2018: none · 2019: 1 paper
Papers 3
- SMARCAD1 Promotes Pancreatic Cancer Cell Growth and Metastasis through Wnt/β-catenin-Mediated EMT. Co-author DOI 10.7150/ijbs.29562↗
- The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0624-9↗
- Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Co-author DOI 10.18632/oncotarget.15692↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yao Zong YUAN · 3 shared papers, 2017–2019 · strength 0.23
- Paper SMARCAD1 Promotes Pancreatic Cancer Cell Growth and Metastasis through Wnt/β-catenin-Mediated EMT. DOI 10.7150/ijbs.29562↗
- Paper The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreati… DOI 10.1186/s12943-017-0624-9↗
- Paper Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta… DOI 10.18632/oncotarget.15692↗
- Pingting Zhou · 2 shared papers, 2017 · strength 0.14
- Paper The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreati… DOI 10.1186/s12943-017-0624-9↗
- Paper Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta… DOI 10.18632/oncotarget.15692↗
- Dong Li · 1 shared paper, 2019 · strength 0.09
- Dong Li · 1 shared paper, 2017 · strength 0.07
- Bo Li · 1 shared paper, 2017 · strength 0.07
- Bo Li · 1 shared paper, 2017 · strength 0.07
- Yanyan Li · 1 shared paper, 2017 · strength 0.07
- Dong Li · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.